AI-Driven Virtual Reality Program Targets Menopause Symptoms
A groundbreaking study reveals how AI and VR can enhance access to cognitive behavioral therapy for menopause management.
Around 80% of midlife women experience vasomotor symptoms like hot flashes.
Only 1.7% of U.S. women used hormone therapy in 2023, highlighting a need for alternative treatments.
The MenoZen VRTM program shows promise in providing personalized, nonpharmacologic interventions.
A recent study indicates that artificial intelligence (AI) and virtual reality (VR) could revolutionize the management of menopause symptoms, particularly through cognitive behavioral therapy (CBT). This innovative approach aims to address the significant barriers women face in accessing effective treatments. The findings will be shared at the upcoming Annual Meeting of The Menopause Society in San Diego, scheduled for October 20-24, 2026.
Menopause symptoms, notably hot flashes and night sweats, affect approximately 80% of women in midlife. These vasomotor symptoms, along with sleep disturbances and mood changes, can severely impact daily life. While hormone therapy is traditionally viewed as the primary pharmacological solution, recent statistics reveal that only 1.7% of women in the U.S. opted for this treatment in 2023. This low usage rate has prompted an increased focus on nonpharmacologic alternatives, including CBT, which has proven effective but remains underutilized due to limited access to providers.
To tackle this issue, researchers have developed a novel AI-VR program named MenoZen VRTM, specifically designed for managing menopause symptoms. In a small-scale multicenter study, participants aged 45 to 60, who reported more than 28 hot flash episodes per week and were not using hormone therapy, engaged with the MenoZen VRTM program using a Meta Quest 3S headset. The program features an AI-VR avatar named Maia, who guides users through various therapeutic modules, including CBT, mindfulness, and breathing exercises.
Preliminary findings suggest that midlife women are enthusiastic about utilizing personalized, nonpharmacologic interventions like MenoZen VRTM. This study highlights the feasibility and acceptability of AI-VR programs in delivering evidence-based therapies, potentially reducing symptom burden and enhancing quality of life while addressing accessibility challenges.
Dr. Karisma Suchak, the lead author from the Cedars-Sinai Center for Virtual Medicine, emphasized the importance of this research. Dr. Stephanie Faubion, medical director for The Menopause Society, noted that while larger studies are necessary to confirm clinical effectiveness, the initial results indicate that AI-enhanced VR could significantly improve access to CBT and other evidence-based treatments for women navigating menopause.
